SOME EFFECTS OF HUMAN GROWTH HORMONE ON RENAL HEMODYNAMICS AND ON TUBULAR PHOSPHATE TRANSPORT IN MAN *

BY JACQUES CORVILAIN AND MAURICE ABRAMOW WITH THE TECHNICAL ASSISTANCE OF A. BERGANS

(From the Clinique Médicale et Laboratoire de Médecine Expérimentale de l'Hôpital Brugmann et de la Fondation Médicale Reine Elisabeth, Université Libre de Bruxelles)

(Submitted for publication November 29, 1961; accepted February 22, 1962)

It has been repeatedly shown that human growth hormone (HGH) affects phosphorus metabolism in patients with hypopituitarism and in normal subjects. Injection of HGH leads to a decrease of urinary phosphorus within a day (1-3). Whereas serum phosphorus does not change or rises only slightly in short-term experiments (1), it has been reported that it rises with long-term treatment (4). Whereas the decrease of urinary phosphorus associated with an unchanged or rising serum phosphorus suggests that growth hormone decreases renal clearance of phosphate, the mechanism for these effects has not been defined. In the dog, growth hormone has been shown to raise glomerular filtration rate (GFR), renal plasma flow (RPF), tubular maximal secretion of para-aminohippurate (TmPAH) (5-7), and tubular maximal reabsorption of sulfate (TmSO4) (8). Effects on renal phosphate clearance have not been reported. The present study was undertaken to determine whether HGH affects the ability of the human kidney to reabsorb phosphate. For this purpose, maximum tubular phosphate reabsorption (TmP04) was measured before and after administration of growth hormone. Effects of the hormone on GFR and on RPF were also studied.

The results indicate that HGH increases the phosphate Tm, the GFR, and the RPF.

MATERIAL AND METHODS

Growth hormone was extracted from human pituitary glands removed at autopsy and stored in acetone. Two lots were used in this study: one prepared by Dr. Maurice Raben, and one prepared by ourselves with Raben's method (9). The HGH was dissolved in 1.5 ml of 0.1 N HCl per 100 mg of dry powder, and then diluted with distilled water until 100 mg was contained in 25 ml of solution. The final pH of the solution was about 3.5.

Injections were given intramuscularly once a day at 7 a.m. Eleven male subjects were studied: one dwarf with hypopituitarism, one hypophysectomized former acromegalic, and nine subjects free of endocrinologic disorders. Brief case descriptions are given in the Appendix.

Plan of study. All patients were hospitalized and received constant diets throughout the study. Water intake was ad libitum. After an adjustment period of 5 days, urine was collected in 24-hour pools for determination of nitrogen, phosphorus, sodium, potassium, and calcium. GFR, TmPAH, and RPF were measured at the end of the control period which lasted 5 days, and on the fourth day of treatment with growth hormone. Treatment with growth hormone was begun on the third day after the control determination of renal function and was continued for 4 days.

Renal studies were begun at 8.30 a.m., after food had been withheld for 14 hours. The bladder was catheterized with a rubber catheter, which remained in place throughout the experiment. (For two individuals, VP and DF, who were able to void at will, catheterization was omitted.) Large amounts of water were given by mouth to maintain urine volume. Blood was drawn for blank determination and for control blood phosphorus, and a priming dose of inulin and phosphate was administered (25 to 50 ml of a 10 per cent inulin solution; 30 to 80 ml of a solution containing Na2HPO4·12 H2O, 10 per cent, and KH2PO4, 0.75 per cent, infused over a period of 3 minutes). A sustaining solution containing inulin and phosphate was then infused at a rate designed to give a slowly rising serum phosphorus value in the range of 7 to 11 mg per 100 ml and a serum inulin value of about 30 mg per 100 ml. Thirty minutes after the infusion was begun, urine was collected for seven consecutive periods, varying in length from 10 to 15 minutes. During the first, third, fifth, and seventh periods, blood was drawn from an antecubital vein. Each period was ended by washing the bladder with distilled water and air. At the end of the seventh period, the infusion of inulin and phosphorus was stopped, and some of the subjects were given a priming dose of PAH (2 ml of a 20 per cent solution) followed by a sustaining infusion.

---

* This work was supported in part by grants from the Paul Govaerts Foundation and the Lekime-Ropsy Foundation.
such as to maintain a plasma level of PAH of 1.5 to 3.5 mg per 100 ml. Thirty minutes after this infusion was begun, urine was collected over four periods of about 10 minutes' duration. Blood was drawn for PAH determination during the first, second, and fourth periods.

**Chemical methods.** Inulin was determined in plasma and urine by the method of Roe, Epstein and Goldstein (10); PAH by the method of Smith and associates (11); inorganic phosphorus by the method of Fiske and Subbarow (12); calcium by the method of Tisdall and Kramer (13); nitrogen by micro-Kjeldahl; and potassium and sodium on a flame photometer.

**Calculations.** Plasma phosphate, inulin, and PAH concentrations were plotted against time to permit interpolation. Plasma values for a given collection period were assumed to be those 2.5 minutes before the midpoint (14). Clearances of inulin and PAH were calculated in the usual manner. Filtered phosphorus was calculated as the product of the inulin clearance and plasma P. Reabsorbed P was calculated as the difference between the filtered and the excreted P.

In each experiment, a maximal tubular reabsorption rate of phosphorus (TmP) is thought to have been reached. This can be inferred from data in Table II (ratio of filtered P to Tm has always been higher than 2).

Reabsorption of P (TmP) per unit of filtrate was also calculated as TmP divided by GFR.

**RESULTS**

**Clinical effects of HGH.** HGH caused transient pain at the site of injection. Four patients complained of moderate anorexia during the treatment period.

**Metabolic effects of HGH (Table I).** Table I shows the effects of HGH compared to control figures on urinary nitrogen, potassium, phosphorus, calcium, and sodium in the 11 studies. In ten patients there was a marked reduction of urinary N during treatment; in nine of them the decrease in urinary N was accompanied by decreases in urinary K, P, and Na; in one of them (DP) there was a decrease in urinary N and K but no appreciable change in urinary P or Na. In one patient (GL) HGH did not induce retention of N, K, P, or Na. In this patient (vide infra) serum phosphorus did not change. Inasmuch as HGH failed to induce N retention in this patient, the data are excluded from the statistical analysis. Calciuria increased in ten patients during HGH treatment.

In Patient BL, who formerly had acromegaly and diabetes, with relief of diabetes after hypophysectomy, HGH was prolonged for 2 days after completion of the renal function studies. The serum glucose, which had remained normal until that time, increased, and glycosuria appeared and continued for several days after HGH was stopped.

The serum phosphorus rose during treatment with HGH in eight patients (Table II). The difference between groups was significant at the 5 per cent level.

**Effects of HGH on renal function (Table II).** The effects of HGH on renal function are compared with control determinations in Table II. As with the metabolic data, the results for Patient GL, who showed no metabolic response to HGH, are excluded from the statistical analysis.

**Glomerular filtration rate.** GFR increased in nine of the subjects. Results were significant at the 0.1 per cent level.
Renal plasma flow. Renal plasma flow was measured in seven of the studies. It increased in all subjects with HGH, and the change was significant at the 1 per cent level. In all subjects the rise in RPF was of the same order of magnitude as the rise in GFR, and the filtration fraction did not change significantly.

Phosphorus Tm. The TmPO₄ increased markedly in all patients, and the change was significant at the 0.1 per cent level. The Tm per unit of GFR increased in nine of the subjects and the change was significant at the 0.1 per cent level. It is of interest that Subject DP, in whom Tm per unit GFR did not increase, was the one who showed the least P retention with HGH. In Subject GL, who showed no metabolic response to HGH, there was a small rise in GFR and RPF, but TmP and TmP per unit of GFR fell slightly (Table II).

**DISCUSSION**

It is known from previous studies (1-3, 15) that human growth hormone, in contrast to animal growth hormone, is metabolically active in man. The present results confirm these findings: in most of our subjects, HGH induced marked retention of N, K, and P, suggesting protein anabolism. Only one subject, the oldest of the series, failed to exhibit this anabolic response to HGH.

A pronounced Na retention was also generally seen. Although this phenomenon is not yet clearly understood, the adrenal cortex does not seem to play a determinant role in its appearance (2).

The increased calciuria that we observed is a frequent finding in HGH studies. Its magnitude appears to be related to HGH dosage (15). The mechanism by which hypercalciuria is elicited by HGH remains controversial: an increased intestinal absorption of Ca, which has been observed with HGH (1), is sometimes insufficient to account for this rise in urinary Ca (2) and bones have been postulated as a source of this extra calcium (16).

A rising serum phosphorus with HGH, without concomitant rise in urinary phosphorus, suggested that the phenomenon might be of renal origin, and studies of renal phosphate clearance were accordingly instituted. It is generally be-
lieved that phosphate excreted in the urine represents the excess of the phosphate filtered over that reabsorbed by the tubules. It is also generally believed that phosphate reabsorption reaches Tm values at high plasma levels and that Tm is independent of the GFR (17–19). Some investigators, however, have suggested that phosphate reabsorption is dependent upon the amount filtered at all plasma levels, and have attributed differences in reabsorption to differences in the number of nephrons functioning (20). To measure the renal capacity for excretion of P, we have used the classical test of TmP under phosphate loading with simultaneous determination of GFR by inulin clearance.

Our control values for TmP are somewhat lower than those found by many investigators, perhaps because our patients suffered from chronic diseases and prolonged hospitalization. Our control values do not, indeed, fall outside the range found by Thompson and Hiatt (19) in normal young male subjects.

In the subjects who exhibited a metabolic response to HGH, TmP increased as early as 4 days after initiation of treatment. The GFR and the RPF increased pari passu, and the filtration fraction did not change. If TmP is indeed independent of GFR, these results indicate that HGH affects kidney function in two ways: it enhances maximal tubular reabsorption of P, and it increases RPF and GFR. If, on the other hand, TmP is indeed a function of filtered phosphate, the rise in TmP observed in these studies might result solely from the increase of filtration rate. However, the rise in TmP was relatively greater than the rise in filtered phosphate, indicating an action of HGH on P reabsorption independent of any action on filtration of P.

It has been suggested that glomeruli may function intermittently in the normal subject. Accordingly, the rise in GFR and RPF with HGH might indicate an increase in the active nephron population. This again would explain some of the increase of TmP observed in these studies. It would not explain the relative excess of the increase in TmP over that of GFR which, as stated above, suggests a tubular effect of HGH on P reabsorption.

The data clearly indicate that HGH increases the reabsorption of P per milliliter of filtrate. In these conditions, the net result of HGH action on renal hemodynamics and tubular transport of P must be, at constant level of P in plasma, an initial fall in urinary excretion of P. This fall would not be expected to occur if the rise in TmP were smaller than, or of the same magnitude as, the rise in GFR and the resulting increase in filtered P. It is of interest that Patient DP, who showed an increase in TmP but no rise in TmP per milliliter of filtrate, was the only subject in this study who did not show appreciable retention of P with HGH, in spite of retention of N. We can reasonably conclude that the decrease in phosphaturia that we have observed in the metabolic studies is of renal origin.

Gershberg (21) also concluded that HGH induces retention of P by increasing renal reabsorption of P. In five patients in whom clearances of P and of creatinine were determined for 24-hour periods, he found that the ratio TRP/GFR was increased with HGH.

In our study, an elevation of serum P was seen as early as 4 days after the initiation of treatment with HGH. The increment was small, but in the face of marked synthesis of protoplas, which might be expected to enhance tissue avidity for P, it gains in significance. Our data suggest that an increase in tubular reabsorption of P per milliliter of filtrate is responsible for this rise in serum P.

The present studies do not necessarily indicate that the effect of HGH on tubular reabsorption of P is a direct one. The parathyroids are known to affect TmP (22, 23) and HGH might affect the renal tubules by inhibiting parathyroid activity. Indeed the enhancement of gastrointestinal absorption of calcium, which may occur during treatment with HGH (1), might be expected to inhibit parathyroid activity. It has been shown, however, that retention of P, with rise of serum P, can be induced by HGH in a subject without parathyroids (24), so that a change in parathyroid activity cannot alone explain this action of HGH.

Our finding that HGH increases GFR and RPF in man confirms previous reports in the dog (5–7), and the previous reports of a similar effect, as judged from 24-hour creatinine clearance, in man (21). It agrees well also with the reports (25–27) that GFR and RPF may be high in patients with acromegaly.
SUMMARY AND CONCLUSIONS

Human growth hormone was administered to 11 human subjects under conditions of metabolic balance regimen. Significant increase in glomerular filtration rate and renal plasma flow was observed. In ten subjects there was a rise in maximal tubular reabsorption of P; in nine, the P reabsorption per milliliter of glomerular filtrate rose as well. The nine subjects who showed the increase of P reabsorption per milliliter of glomerular filtrate also retained P with human growth hormone. On the fourth day of treatment with human growth hormone, serum P was raised in eight subjects. It is concluded that growth hormone is responsible for the elevation of serum P found in acromegaly, and that this is effected by an increase in the reabsorption of filtered P.

Growth hormone thus appears to have a direct effect upon tubular transport of P. This effect appears to be opposite to that of parathyroid hormone.

ACKNOWLEDGMENT

We are much indebted to Dr. F. C. Barter for having reviewed our manuscript. We wish to thank Dr. M. S. Raben for his generous assistance in preparing human growth hormone. We are also most grateful to Prof. L. Desclin and Dr. C. Gompel for providing us with an ample supply of human pituitaries, and to Prof. P. A. Bastenie for the opportunity to study some of the patients in his department.

APPENDIX

The case material was as follows.

VHF, age 26: dwarf with idiopathic hypopituitarism who had not received any hormonal treatment for the last 9 years.

BL, age 44: man with acromegaly. Because of severe diabetes, hypophysectomy had been performed 2 years previously. After the operation, hyperglycemia and glycosuria had disappeared completely and no insulin was required. Cortisone, 25 mg per day, was given as substitutive therapy and maintained during the whole study with HGH.

LR, age 26; SA, age 29; RM, age 33: men with pulmonary tuberculosis (under treatment) in good general condition.

SG, age 36: man with chronic occupational lead poisoning and mild impairment of renal function.

GL, age 53: man with emphysema and asthma.

VC, age 28: man with rectocolic polyposis and intermittent diarrhea.

DP, age 26: man convalescent from pharyngitis.

VP, age 33: man with chronic alcoholism.

DJ, age 27: man convalescent from acute colitis.

REFERENCES


